ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study [Yahoo! Finance]
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The phase II INVOKE-2 study evaluated the safety and efficacy of AL002 in slowing disease progression in individuals with early AD. The study's primary endpoint was to check disease progression, as measured by the Clinical Dementia Rating Sum of Boxes (“CDR-SB”) scale. The CDR-SB is a numerical scale that measures the severity of the AD indication. In the study, treatment with AL002 failed to meet the primary endpoint of slowing Alzheimer's clinical progression as measured by the CDR-SB. Also, no treatment effects favored AL002 on secondary clinical and functional endpoints in the INVOKE-2 study. The stock hit its 52-week low on the pipeline setback. Year to date, shares of Alector have plunged 67.8% compared with the industry's 7.8% decline. Image Source: Zacks Investment Research Data from the INVOKE-2 study demonstrated no significant effects on Alzheimer's fluid biomarkers favoring AL002, as well as amyloid PET imaging showed no treatment-related reduction of brain amyloi
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector, Inc. (NASDAQ: ALEC) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $9.00.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) had its price target lowered by analysts at HC Wainwright from $35.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) had its price target lowered by analysts at BTIG Research from $16.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $3.00 price target on the stock, down previously from $10.00.MarketBeat
ALEC
Earnings
- 11/6/24 - Beat
ALEC
Sec Filings
- 12/6/24 - Form SC
- 12/3/24 - Form 4
- 12/3/24 - Form 4
- ALEC's page on the SEC website